Biotech

All Articles

OS Treatments refiles $6M IPO to cash HER2 drug, preclinical ADCs

.OS Therapies will certainly note on the NYSE American sell substitution this morning via a $6.4 mil...

ALX's waning CD47 reaction cost sends out stock spiraling down

.ALX Oncology's period 2 gastric cancer cells action price has diminished. After viewing its CD47 bl...

Ionis axes eye ailment coming from targets of Roche-partnered prospect after data disappoint

.One More of Ionis Pharmaceuticals' key midphase readouts has actually disappointed desires, prompti...

Biogen's CEO mentioned no high-risk sell 2023. He's ready to become bold

.While Biogen's pharma peers are actually hunting for late-stage possessions with little bit of risk...

Instil refills pipe in $2B biobucks take care of ImmunOnco

.Instil Biography has actually been a biotech looking for a pipeline after it scrapped its lead poss...

Biogen leaves Denali Alzheimer's collab

.Biogen has restored civil liberties to a very early Alzheimer's ailment course to Denali Therapies,...

Takeda faucets new head people oncology organization-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, firings ...

Vertex, beaten by AATD once more, loses 2 properties on throw out stack

.Vertex's attempt to alleviate an unusual genetic disease has actually struck yet another drawback. ...

Vir increases 3 T-cell engagers coming from Sanofi, lays off 25% of staff

.Vir Biotechnology's second-quarter incomes report had not been short of big information. The compan...

Galapagos stops CAR-T cell therapy trial over Parkinsonism situation

.Galapagos has stopped enrollment in a test of a BCMA-directed CAR-T cell treatment, pushing the bra...